{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=COPD+Patients",
    "query": {
      "condition": "COPD Patients"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 543,
    "total_pages": 55,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=COPD+Patients&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T18:13:12.937Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05001009",
      "title": "Goals of Care Conversations Study",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Seriously Ill Patients",
        "Cancer",
        "Heart Failure",
        "Interstitial Lung Disease",
        "Chronic Obstructive Pulmonary Disease",
        "End-stage Renal Disease",
        "End-stage Liver Disease",
        "Dementia"
      ],
      "interventions": [
        {
          "name": "Clinician Implementation Strategy Stage 1: low intensity clinician training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Clinician Implementation Strategy Stage 2: high intensity clinician training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Low patient engagement",
          "type": "BEHAVIORAL"
        },
        {
          "name": "High patient engagement",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2022-09-13",
      "completion_date": "2025-09-30",
      "has_results": false,
      "last_update_posted_date": "2024-12-27",
      "last_synced_at": "2026-07-23T18:13:12.937Z",
      "location_count": 3,
      "location_summary": "Palo Alto, California • West Los Angeles, California • Aurora, Colorado",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "West Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05001009"
    },
    {
      "nct_id": "NCT07125053",
      "title": "COPD Resources, Education, and Activity Designed for You Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Education (self-guided)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Education (counselor-led)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Physical Activity",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Inhaler Training",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 448,
      "start_date": "2025-08-18",
      "completion_date": "2029-09-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-07-23T18:13:12.937Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07125053"
    },
    {
      "nct_id": "NCT04361552",
      "title": "Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cerebrovascular Accident",
        "Chronic Obstructive Pulmonary Disease",
        "Chronic Renal Failure",
        "Coronary Artery Disease",
        "Diabetes Mellitus",
        "Malignant Neoplasm",
        "SARS Coronavirus 2 Infection"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Tocilizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-04-07",
      "completion_date": "2020-06-02",
      "has_results": false,
      "last_update_posted_date": "2020-06-18",
      "last_synced_at": "2026-07-23T18:13:12.937Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04361552"
    },
    {
      "nct_id": "NCT01154400",
      "title": "Hydrolyzed Casein and Whey Protein Supplementation and the Addition of Leucine to Induce Protein Anabolism in Malnourished COPD Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Casein protein hydrolysates",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Whey protein hydrolysates",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Casein protein hydrolysates + LEU",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Whey protein hydrolysates + LEU",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Texas A&M University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2009-05",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2012-10-15",
      "last_synced_at": "2026-07-23T18:13:12.937Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01154400"
    },
    {
      "nct_id": "NCT05181826",
      "title": "Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer",
        "Liver Cirrhosis",
        "Chronic Hepatitis",
        "Hepatitis B",
        "Hepatitis C",
        "Diabetes",
        "COPD"
      ],
      "interventions": [
        {
          "name": "Multi-analyte Blood Test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Helio Genomics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1200,
      "start_date": "2019-05-21",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-07-23T18:13:12.937Z",
      "location_count": 7,
      "location_summary": "Redondo Beach, California • Coon Rapids, Minnesota • Fridley, Minnesota + 4 more",
      "locations": [
        {
          "city": "Redondo Beach",
          "state": "California"
        },
        {
          "city": "Coon Rapids",
          "state": "Minnesota"
        },
        {
          "city": "Fridley",
          "state": "Minnesota"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05181826"
    },
    {
      "nct_id": "NCT01525615",
      "title": "A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Respimat inhaler",
          "type": "DEVICE"
        },
        {
          "name": "tiotropium+olodaterol (low dose)",
          "type": "DRUG"
        },
        {
          "name": "tiotropium + olodaterol (high dose)",
          "type": "DRUG"
        },
        {
          "name": "placebo to tiotropium+olodaterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 404,
      "start_date": "2012-02",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2016-08-29",
      "last_synced_at": "2026-07-23T18:13:12.937Z",
      "location_count": 15,
      "location_summary": "Torrance, California • Hartford, Connecticut • Springfield, Illinois + 12 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Livonia",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01525615"
    },
    {
      "nct_id": "NCT02796651",
      "title": "Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease - COPD"
      ],
      "interventions": [
        {
          "name": "Formoterol fumarate (6 μg)",
          "type": "DRUG"
        },
        {
          "name": "Formoterol furmarate (20 μg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for formoterol fumarate",
          "type": "DRUG"
        },
        {
          "name": "Formoterol fumarate (12 μg)",
          "type": "DRUG"
        },
        {
          "name": "Formoterol fumarate (40 μg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "40 Years to 130 Years"
      },
      "enrollment_count": 132,
      "start_date": "2016-06-30",
      "completion_date": "2016-12-07",
      "has_results": true,
      "last_update_posted_date": "2018-02-07",
      "last_synced_at": "2026-07-23T18:13:12.937Z",
      "location_count": 20,
      "location_summary": "Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 17 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Celebration",
          "state": "Florida"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02796651"
    },
    {
      "nct_id": "NCT00630227",
      "title": "Biologic Lung Volume Reduction (BLVR) Phase 2 Homogeneous Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Homogeneous Emphysema"
      ],
      "interventions": [
        {
          "name": "Biologic Lung Volume Reduction",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Aeris Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2008-02",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2011-10-24",
      "last_synced_at": "2026-07-23T18:13:12.937Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Iowa City, Iowa + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Topeka",
          "state": "Kansas"
        },
        {
          "city": "Towson",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00630227"
    },
    {
      "nct_id": "NCT02238483",
      "title": "A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease COPD"
      ],
      "interventions": [
        {
          "name": "AZD7624 1.0 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 213,
      "start_date": "2014-10-28",
      "completion_date": "2016-04-04",
      "has_results": true,
      "last_update_posted_date": "2018-05-24",
      "last_synced_at": "2026-07-23T18:13:12.937Z",
      "location_count": 20,
      "location_summary": "Los Angeles, California • Torrance, California • Denver, Colorado + 17 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02238483"
    },
    {
      "nct_id": "NCT03937479",
      "title": "Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 416,
      "start_date": "2019-05-01",
      "completion_date": "2019-11-15",
      "has_results": true,
      "last_update_posted_date": "2020-11-20",
      "last_synced_at": "2026-07-23T18:13:12.937Z",
      "location_count": 50,
      "location_summary": "Anniston, Alabama • Fullerton, California • Los Angeles, California + 44 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lafayette",
          "state": "Colorado"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03937479"
    }
  ]
}